Please use this identifier to cite or link to this item: http://repo.knmu.edu.ua/handle/123456789/23476
Full metadata record
DC FieldValueLanguage
dc.contributor.authorВізір, Марина Олександрівна-
dc.contributor.authorVizir, Maryna-
dc.contributor.authorIipinge, Emilie-
dc.contributor.authorВизир, Марина Александровна-
dc.contributor.authorIraqi, Hamza-
dc.date.accessioned2019-06-14T10:53:43Z-
dc.date.available2019-06-14T10:53:43Z-
dc.date.issued2019-05-01-
dc.identifier.citationVizir M. Carvedilol vs propranolol in treatment of portal hypertension in cirrhotic patients with oesophageal varices / М. Vizir, E. Iipinge, H. Iraqi // Инновационные подходы к диагностике и лечению терапевтических заболеваний : материалы республиканской юбилейной научно-практической конференции, Ташкент, 1–2 мая 2019 г. – Ташкент, 2019. – P. 24.ru_RU
dc.identifier.urihttps://repo.knmu.edu.ua/handle/123456789/23476-
dc.description.abstractPortal hypertension occurs in most patient with liver cirrhosis. Carvedilol a non-selective beta-blocker with intrinsic alpha-1 blocker activity has a greater reduction of portal pressure in patients with portal hypertension than Propranolol. In almost 90% of patients with cirrhosis oesophageal varices can be found and about 30% of that varices are at risk of bleeding. The estimated death rate for first episode of variceal haemorrhage is 30-50%.ru_RU
dc.language.isoenru_RU
dc.subjectCarvedilolru_RU
dc.subjectpropranololru_RU
dc.subjectoesophageal varicesru_RU
dc.titleCarvedilol vs propranolol in treatment of portal hypertension in cirrhotic patients with oesophageal varicesru_RU
dc.typeThesisru_RU
Appears in Collections:Наукові роботи молодих вчених. Кафедра внутрішньої медицини № 1

Files in This Item:
File Description SizeFormat 
ВизирМАХарьков1.docx14,92 kBMicrosoft Word XMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.